Company news
Neurizon Therapeutics Limited news in 2023
Neurizon Therapeutics Limited's news releases, calls and decks from 2023, newest first.
FightMND Invites PharmAust to Apply for Phase 2/3 Funding
December 21, 2023
PharmAust Receives R&D Tax Incentive Refund
December 20, 2023
93% take up in Options Offer
December 14, 2023
PharmAust Raises $3.5 Million at a Premium
December 12, 2023
PAA completes Phase 1 and files for Orphan Drug Designation
November 30, 2023
Prospectus & Target Market Determination
November 21, 2023
Appendix 4C and Quarterly Update
October 29, 2023
Options Offer to Existing Listed Option Holders
October 17, 2023
Final MND Patient in Cohort 4 Successfully Completes Dosing
October 12, 2023
Canine Oncology Data Supports Progression to Registration
October 8, 2023
Appendix 4E & Full Year Statutory Accounts
August 31, 2023
Chief Executive Officer Appointment
August 27, 2023
Additional Phase 1 data suggest MPL may inhibit MND
August 21, 2023
Cohort 3 Pharmacokinetics in MND Patients Completed
August 8, 2023
Epichem enters voluntary liquidation
July 31, 2023
MND Trial Successfully Completes 3rd Patient Cohort
July 27, 2023
Canine Trial Update
July 13, 2023
Results show MPL suppresses biomarkers associated with MND
July 11, 2023
Louie the Beagle surpasses one year on MPL
July 5, 2023
MND Biomarkers and Pharmacodynamics Results
July 4, 2023
Motor Neurone Disease Phase 1/2 Clinical Trial Update
June 26, 2023
PharmAust MND Trial Interim Analysis PK Outcomes
June 6, 2023
Motor Neurone Disease Clinical Trial Update
May 21, 2023
Progress update on Phase 1/2 MND interim analysis
May 15, 2023
Independent tests show MPL retains long-term shelf-life
May 9, 2023
MPL has anti-cancer effects across multiple cancer types
May 8, 2023
PharmAust Raises $2.5m via Placement
May 3, 2023
MND Trial Successfully Completes Second Patient Cohort
April 27, 2023
Arrival of additional MPL tablets
April 16, 2023
PharmAust launches international CEO search
April 12, 2023
MND Trial Completes Enrolment of Cohort 2
March 29, 2023
Stable Patient in MND trial reaches 6-months on MPL
March 27, 2023
Canine Cancer Trial Update
March 6, 2023
Interim analysis recommended in MND trial
March 1, 2023
European Patent relating to MPL Combinations in Cancer
February 27, 2023
First Patient of Cohort 2 Dosed in MND Trial
February 19, 2023
PharmAust canine trial update
February 9, 2023
PharmAust Progresses to Elevated Doses in MND Patients
January 19, 2023
MND Trial Successfully Completes First Patient Cohort
January 5, 2023
Decks in 2023
- PharmAust — Non-Deal Roadshow (May 2023)
Roadshow · 15 slides · May 2023
- PharmAust — AOG Energy Conference 2023
Conference · 18 slides · Mar 15, 2023